Skip to content

Effect of scraping combined with pricking-cupping therapy in CAM on the symptoms and future risks of stable COPD

Effect of scraping combined with pricking-cupping therapy in CAM on the symptoms and future risks of stable COPD

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083527
Enrollment
Unknown
Registered
2024-04-26
Start date
2022-01-01
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Guasha group:Guasha therapy
Guasha combined with blood-letting puncture plus cupping group:Guasha combined with blood-letting puncture plus cupping therapy
Sham Guasha group:sham Guasha therapy

Sponsors

Tianjin Haihe Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) It meets the diagnostic criteria of COPD and is currently in stable COPD; (2) Age between 40 and 75 years old, regardless of gender; (3) There is a definite history of recurrent attacks before the first treatment, and the case data is relatively complete; (4) The patient has never received scraping therapy; (5) The patient has informed consent and can adhere to examination, treatment, and follow-up according to the research requirements.

Exclusion criteria

Exclusion criteria: (1) AECOPD; (2) Exclude bronchial asthma, interstitial lung disease, lung cancer and other chronic lung diseases requiring intervention or treatment; Patients with severe respiratory, circulatory, urinary, blood, nervous and endocrine system diseases, mental patients, malignant tumors, infectious diseases; (3) Patients who have received non-drug therapy with other TCM characteristics in the past six months; (4) Pregnant or lactating women; (5) Scraping site with skin damage or cicatricial constitution; (6) Drug abuse; Alcohol abuse and could not be terminated during the study; (7) The researcher does not consider it appropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
pulmonary function test;6MWT;Arterial blood gas analysis;Number of acute exacerbations and hospitalizations;

Secondary

MeasureTime frame
Quality of life score;TCM constitution score;Influence of western drug use or treatment ladder;

Countries

China

Contacts

Public ContactMa Zhaorun

Tianjin Haihe Hospital

tammycheung@yeah.net+86 189 2018 0131

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026